{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:48:42Z","timestamp":1792532922985,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10147-020-01761-3","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T12:03:20Z","timestamp":1596888200000},"page":"2107-2114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-8915","authenticated-orcid":false,"given":"Yoichiro","family":"Tohi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Mitsuzuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Hashine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kakehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"1761_CR1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","volume":"167","author":"R Choo","year":"2002","unstructured":"Choo R, Klotz L, Danjoux C et al (2002) Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and\/or clinical progression. J Urol 167:1664\u20131669","journal-title":"J Urol"},{"key":"1761_CR2","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","volume":"33","author":"JJ Tosoian","year":"2015","unstructured":"Tosoian JJ, Mamawala M, Epstein JI et al (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33:3379\u20133385","journal-title":"J Clin Oncol"},{"key":"1761_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L, Vesprini D, Sethulavalan P et al (2015) Long-term following-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272\u2013277","journal-title":"J Clin Oncol"},{"key":"1761_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.eururo.2016.03.048","volume":"70","author":"RA Godtman","year":"2016","unstructured":"Godtman RA, Holmberg E, Khatami A et al (2016) Long-term results of active surveillance in the Goteborg randomized, population-based prostate cancer screening trial. Eur Urol 70:760\u2013766","journal-title":"Eur Urol"},{"key":"1761_CR5","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology prostate cancer version 1.2020"},{"key":"1761_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618\u2013629","journal-title":"Eur Urol"},{"key":"1761_CR7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/iju.13380","volume":"24","author":"Y Kakehi","year":"2017","unstructured":"Kakehi Y, Sugimoto M, Taoka R (2017) Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol 24:648\u2013666","journal-title":"Int J Urol"},{"key":"1761_CR8","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.eururo.2015.06.012","volume":"68","author":"LP Bokhorst","year":"2015","unstructured":"Bokhorst LP, Alberts AR, Rannikko A et al (2015) Compliance rates with the prostate cancer research international active surveillance (PRIAS) protocol and disease reclassification in noncompliers. Eur Urol 68:814\u2013821","journal-title":"Eur Urol"},{"key":"1761_CR9","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","volume":"70","author":"LP Bokhorst","year":"2016","unstructured":"Bokhorst LP, Valdagni R, Rannikko A et al (2016) A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 70:954\u2013960","journal-title":"Eur Urol"},{"key":"1761_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00345-014-1453-8","volume":"33","author":"M Sugimoto","year":"2015","unstructured":"Sugimoto M, Hirama H, Yamaguchi A et al (2015) Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. World J Urol 33:981\u2013987","journal-title":"World J Urol"},{"key":"1761_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.eururo.2007.05.011","volume":"52","author":"RCN van den Bergh","year":"2007","unstructured":"van den Bergh RCN, Roemeling S, Roobol MJ et al (2007) Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 52:1560\u20131563","journal-title":"Eur Urol"},{"key":"1761_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb S, Vellekoop A, Ahmed HU et al (2013) Systematic review of complications of prostate biopsy. Eur Urol 64:876\u2013892","journal-title":"Eur Urol"},{"key":"1761_CR13","doi-asserted-by":"publisher","first-page":"d7894","DOI":"10.1136\/bmj.d7894","volume":"344","author":"DJ Rosario","year":"2012","unstructured":"Rosario DJ, Lane JA, Metcalfe C et al (2012) Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 344:d7894","journal-title":"BMJ"},{"key":"1761_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eururo.2016.08.004","volume":"71","author":"M Borghesi","year":"2017","unstructured":"Borghesi M, Ahmed H, Nam R et al (2017) Complications after systematic, random, and image-guided prostate biopsy. Eur Urol 71:353\u2013365","journal-title":"Eur Urol"},{"key":"1761_CR15","first-page":"394","volume":"120","author":"PK Chiu","year":"2017","unstructured":"Chiu PK, Alberts AR, Venderbos LDF et al (2017) Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. BJU I 120:394\u2013400","journal-title":"BJU I"},{"key":"1761_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1442-2042.2008.02048.x","volume":"15","author":"Y Kakehi","year":"2008","unstructured":"Kakehi Y, Naito S, Japanese Urological Association (2008) Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan. Int J Urol 15:319\u2013321","journal-title":"Int J Urol"},{"key":"1761_CR17","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bju.13410","volume":"118","author":"LP Bokhorst","year":"2016","unstructured":"Bokhorst LP, Lepist\u00f6 I, Kakehi Y et al (2016) Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: active Surveillance (PRIAS) study. BJU Int 118:366\u2013371","journal-title":"BJU Int"},{"key":"1761_CR18","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.juro.2012.10.005","volume":"189","author":"S Loeb","year":"2013","unstructured":"Loeb S, Cater HB, Berndt SI et al (2013) Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol 189:867\u2013870","journal-title":"J Urol"},{"key":"1761_CR19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.juro.2016.11.081","volume":"197","author":"JA Halpern","year":"2017","unstructured":"Halpern JA, Sedrakyan A, Dinerman B et al (2017) Indications, utilization and complications following prostate biopsy: New York state analysis. J Urol 197:1020\u20131025","journal-title":"J Urol"},{"key":"1761_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.juro.2013.08.088","volume":"191","author":"B Ehdaie","year":"2014","unstructured":"Ehdaie B, Vertosick E, Spaliviero M et al (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191:660\u2013664","journal-title":"J Urol"},{"key":"1761_CR21","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.juro.2016.02.2963","volume":"196","author":"S Loeb","year":"2016","unstructured":"Loeb S, Walter D, Curnyn C et al (2016) How active is active surveillance? Intensity of followup during active surveillance for prostate cancer in the United States. J Urol 196:721\u2013726","journal-title":"J Urol"},{"key":"1761_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/pcan.2016.5","volume":"19","author":"S Fischer","year":"2016","unstructured":"Fischer S, Sun S, Howard LE et al (2016) Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. Prostate Cancer Prostatic Dis 19:202\u2013208","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1761_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/S0090-4295(02)01864-2","volume":"60","author":"T M\u00e4kinen","year":"2002","unstructured":"M\u00e4kinen T, Auvinen A, Hakama M et al (2002) Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology 60:846\u2013850","journal-title":"Urology"},{"key":"1761_CR24","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/bju.14705","volume":"124","author":"AS Glass","year":"2019","unstructured":"Glass AS, Dall\u2019Era MA (2019) Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance. BJU Int 124:730\u2013737","journal-title":"BJU Int"},{"key":"1761_CR25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s10147-015-0831-6","volume":"20","author":"T Namekawa","year":"2015","unstructured":"Namekawa T, Fukasawa S, Komaru A et al (2015) Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events. Int J Clin Oncol 20:1185\u20131191","journal-title":"Int J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s10147-022-02145-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01761-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T02:18:18Z","timestamp":1646273898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01761-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01761-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10147-022-02145-5","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-022-02145-5","URL":"https:\/\/doi.org\/10.1007\/s10147-022-02145-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Nobuo Shinohara received honoraria from Takeda Pharmaceutical Co. Ltd, Bayer Co. Ltd, Astellas Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd, Pfizer Co Ltd, Novartis Pharmaceutical Co. Ltd, and AstraZeneca Co. Ltd, and received research funding from Ono Pharmaceutical Co. Ltd and Astellas Pharmaceutical Co. Ltd. Dr Masatoshi Eto received honoraria from Takeda Pharmaceutical Co. Ltd and Janssen Pharmaceutical Co. Ltd, and received research funding from Sanofi Co. Ltd, Bayer Co. Ltd, Astellas Pharmaceutical Co. Ltd and Takeda Pharmaceutical Co. Ltd. Dr Shin Egawa received scholarship donations from Takeda Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, Ono Pharmaceutical Co. Ltd and Bayer Co. Ltd. Dr Akira Yokomizo received honoraria from Astellas Pharmaceutical Co. Ltd, Sanofi Co. Ltd and Bayer Co. Ltd. Dr Mikio Sugimoto received honoraria from Astellas Pharmaceutical Co. Ltd, Janssen Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd and AstraZeneca Co. Ltd, and received researching funding from Astellas Pharmaceutical Co. Ltd, Janssen Pharmaceutical Co. Ltd, AstraZeneca Co. Ltd, Bayer Co. Ltd, Ono Pharmaceutical Co. Ltd, Shin Nippon Biomedical Laboratories Ltd, Eisai Co. Ltd, and Merck Ltd, and received scholarship donations from Astellas Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Bayer Co. Ltd and Pfizer Co Ltd. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}